Why the study?
Biomarkers play an emerging role in HF monitoring, but their utility as predictors of LV function improvement following immunoadsorption in DCM required analysis.
Do cardiac biomarkers predict improvement in left ventricular function after immunoadsorption treatment in patients with dilated cardiomyopathy?
Do cardiac biomarkers predict improvement in left ventricular function after immunoadsorption treatment in patients with dilated cardiomyopathy?
Acute decreases in high-sensitivity troponins following immunoadsorption treatment correlate with long-term improvement in left ventricular ejection fraction in patients with dilated cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
May support biomarker selection for immunoadsorption in DCM; leaves open validation in prospective trials.
Weinmann et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: